or Try an Advanced Search...

    Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.65 3.71% 0.02
    CTXR closed down 9.15 percent on Wednesday, May 15, 2024, on 2.26 times normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CTXR trend table...
    Date Alert Name Type % Chg
    Below Lower BB Weakness 3.71%
    Lower Bollinger Band Touch Weakness 3.71%
    Golden Cross Bullish -5.77%
    NR7 Range Contraction -5.77%
    NR7-2 Range Contraction -5.77%
    Narrow Range Bar Range Contraction -5.77%
    Inside Day Range Contraction -5.77%
    Gapped Down Weakness -5.77%
    NR7 Range Contraction -6.82%
    Narrow Range Bar Range Contraction -6.82%
    Older End-of-Day Signals for CTXR ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 1 hour ago
    Up 5% about 3 hours ago
    Up 3% about 4 hours ago
    Up 2% about 4 hours ago
    Up 1% about 4 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CTXR Chart by TradingView
    Basic chart:

    Profile

    Citius Pharmaceuticals, Inc. Description

    Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Pharmaceutical Drugs Inflammation Catheter Antibiotics Cancer Care Care Products Prescription Product Prescription Products Acetamides Bloodstream Infections Lidocaine

    Is CTXR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Citius Pharmaceuticals Non-GAAP EPS of -$0.05
    May 14 Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
    May 10 Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
    Apr 30 Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
    Apr 26 Citius Pharmaceuticals to raise $15M through direct offering; shares fall
    Apr 26 Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
    Apr 11 Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
    Apr 4 Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference
    Mar 18 Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment
    Mar 18 Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
    See more CTXR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.4
    52 Week Low 0.6
    Average Volume 1,084,504
    200-Day Moving Average 0.77
    50-Day Moving Average 0.77
    20-Day Moving Average 0.71
    10-Day Moving Average 0.69
    Average True Range 0.07
    RSI (14) 35.48
    ADX 12.72
    +DI 20.42
    -DI 25.65
    Chandelier Exit (Long, 3 ATRs) 0.85
    Chandelier Exit (Short, 3 ATRs) 0.80
    Upper Bollinger Bands 0.79
    Lower Bollinger Band 0.63
    Percent B (%b) -0.04
    BandWidth 22.11
    MACD Line -0.03
    MACD Signal Line -0.03
    MACD Histogram -0.0034
    Fundamentals Value
    Market Cap 99.31 Million
    Num Shares 159 Million
    EPS -0.22
    Price-to-Earnings (P/E) Ratio -2.84
    Price-to-Sales 0.00
    Price-to-Book 1.16
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.74
    Resistance 3 (R3) 0.74 0.71 0.72
    Resistance 2 (R2) 0.71 0.68 0.71 0.71
    Resistance 1 (R1) 0.67 0.66 0.65 0.66 0.71
    Pivot Point 0.63 0.63 0.63 0.63 0.63
    Support 1 (S1) 0.59 0.61 0.58 0.59 0.54
    Support 2 (S2) 0.56 0.59 0.56 0.54
    Support 3 (S3) 0.52 0.56 0.53
    Support 4 (S4) 0.51